Faculty

2007-2013 MD Anderson Cancer Research Center (Supervisor: Michael g. Rosenblum), postdoctoral

2001-2007 Nankai University (Tutor: Baigang), doctor of Science

1996-2000 Liaoning University, Bachelor of Science

2022 present Shenzhen Bay laboratory, special researcher

2017 till now, project leader and distinguished researcher of Shenzhen Graduate School of Peking University

2016-2017 Sorento medical pharmaceutical, senior scientist

2013-2016 Scripps Institute (Supervisor: Peter g. Schultz), Assistant Researcher

In recent years, cancer immunotherapy has attracted much attention and is the focus of cancer treatment. In December 2011, nature and the Journal of Clinical Oncology, the top journal of Clinical Oncology, published a review article with the same title "the era of cancer immunotherapy has come", predicting the significant impact of immune cell therapy on tumor treatment. This research group aims to design and develop precision drug strategies for personalized treatment by strictly investigating the unique anti-tumor mechanism and potential side effects of different immunotherapeutic drugs. By finding the best design scheme for targeting different blood tumors and solid tumors, our research group will develop a new drug development and design platform and prepare new personalized anti-tumor immunotherapy drugs.

1) Lijun Zhao†, Shuhong Li†, Xiaoyi Wei, Xuexiu Qi, Qiaoru Guo, Licai Shi, Ji-Shuai Zhang, Jun Li, Ze-Lin Liu, Zhi Guo, Hongyu Zhang, Jia Feng, Yuanyuan Shi, Suping Zhang,Yu J. Cao*, A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances, Protein & Cell, 2024, Jun 1; Online ahead of print. PMID: 38823002.

2) Qiao-ru Guo,Yu J. Cao*, Applications of genetic code expansion technology in eukaryotes, Protein & Cell, 2024 May 7;15(5):331-363. PMID: 37847216.

3) Dong Liu†, Xuexiu Qi†, Xiaoyi Wei, Lijun Zhao, Xuechun Wang, Shuhong Li, Zhidong Wang, Lisai Shi, Jie-an Xu, Mei Hong, Zhong Liu, Lili Zhao*, Xiankun Wang, Bo Zhang, Yuhan Zhang, Feng Wang,Yu J. Cao*,A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy, Theranostics, 2022, Nov 14;12(18):7788-7803. PMID: 36451856.

4) Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Dong Liu, Lei Liu, Feiqiu Wen, Ji-shuai Zhang, Feng Wang, Ze-lin Liu*,Yu J. Cao*, A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL, Blood, 2022 Oct 20; 140(16): 1790-1802. PMID: 35981465.

5) Yu J. Cao*,†, Chenfei Yu†, Kuan-Lin Wu†, Xuechun Wang, Dong Liu, Zeru Tian, Lijun Zhao, Xuexiu Qi, Axel Loredo, Anna Chung, Han Xiao*. Synthesis of precision antibody conjugates using proximity-induced chemistry, Theranostics, 2021, Aug 27; 11(18):9107-9117. PMID: 34522229.

6) Yu J. Cao*, Xuechun Wang, Zhidong Wang, Lijun Zhao, Shuhong Li, Zhuxia Zhang, Xiaoyi Wei, Hwayoung Yun, Sei-hyun Choi, Zhong Liu, Lili Zhao, Stephanie A. Kazane. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers, ACS Synthetic Biology, 2021, May 21; 10(5):1176-1183. PMID: 33856201(Research Highlight in Nature Chemical Biology).

7) Zhidong Wang,Yu J. Cao*. Adoptive cell therapy targeting neoantigens: a frontier for cancer research, Frontiers in Immunology, 2020, Mar 5; 11: 176-188. PMID: 32194541.

8) Lijun Zhao,Yu J. Cao*. Engineered T Cell Therapy for Cancer in the Clinic, Frontiers in Immunology, 2019, Oct 11; 10: 2250-2269. PMID: 31681259.

9) Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz*,Yu J. Cao*, Feng Wang*. A tumor-targeted immune checkpoint blocker, Proceedings of the National Academy of Sciences, 2019, Aug 6; 116(32):15889-15894. PMID: 31332018.

10) Lawrence H. Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A. Mohamedali,Yu J. Cao, Walter N. Hittelman, Michael G. Rosenblum. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B, Journal of Experimental & Clinical Cancer Research, 2019, Jul 30; 38(1): 332-345. PMID: 31362764.